ReviewFrontiers in pharmacology2026
Mesenchymal stem cells: a potential therapeutic strategy for IgA nephropathy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the predominant primary glomerulonephritis worldwide, characterized by the deposition of IgA-containing immune complexes in the glomerular mesangium. Despite advances in supportive care, there is a lack of IgAN-specific therapies capable of halting IgAN progression. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic target, owing to their immunomodulatory, anti-inflammatory, and tissue repair properties. Accumulating evidence suggests that MSCs hold considerable therapeutic potential for the treatment of IgAN. This review summarizes the potential mechanisms underlying the therapeutic effects of MSCs in IgAN, with a particular focus on their roles in the gut, liver, and kidney, and discusses current challenges and future directions for MSCs-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.